BEXIMCO PHARMA.GDR REGS 1 - Asset Resilience Ratio

Latest as of December 2024: 0.95%

BEXIMCO PHARMA.GDR REGS 1 (R2WA) has an Asset Resilience Ratio of 0.95% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€700.00 Million
≈ $818.37 Million USD Cash + Short-term Investments

Total Assets

€73.80 Billion
≈ $86.28 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2024–2024)

This chart shows how BEXIMCO PHARMA.GDR REGS 1's Asset Resilience Ratio has changed over time. See R2WA financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down BEXIMCO PHARMA.GDR REGS 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of BEXIMCO PHARMA.GDR REGS 1.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €700.00 Million 0.95%
Total Liquid Assets €700.00 Million 0.95%

Asset Resilience Insights

  • Limited Liquidity: BEXIMCO PHARMA.GDR REGS 1 maintains only 0.95% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

BEXIMCO PHARMA.GDR REGS 1 Industry Peers by Asset Resilience Ratio

Compare BEXIMCO PHARMA.GDR REGS 1's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
Drug Manufacturers - Specialty & Generic 5.92%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
Drug Manufacturers - Specialty & Generic 1.18%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.01%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
Drug Manufacturers - Specialty & Generic 0.00%
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401
Drug Manufacturers - Specialty & Generic 5.09%
KPC Pharmaceuticals Inc
SHG:600422
Drug Manufacturers - Specialty & Generic 16.37%

Annual Asset Resilience Ratio for BEXIMCO PHARMA.GDR REGS 1 (2024–2024)

The table below shows the annual Asset Resilience Ratio data for BEXIMCO PHARMA.GDR REGS 1.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-06-30 0.29% €200.00 Million
≈ $233.82 Million
€69.34 Billion
≈ $81.07 Billion
--
pp = percentage points

About BEXIMCO PHARMA.GDR REGS 1

F:R2WA Germany Drug Manufacturers - Specialty & Generic
Market Cap
$208.62 Million
€178.44 Million EUR
Market Cap Rank
#16349 Global
#1560 in Germany
Share Price
€0.40
Change (1 day)
+0.00%
52-Week Range
€0.40 - €0.40
All Time High
€1.17
About

Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskelet… Read more